Completion of Acclaim-1 dose escalation: Recommended Phase 2 dose of quaratusugene ozeplasmid gene therapy and Osimertinib

Authors
Category Primary study
JournalMolecular Cancer Therapeutics
Year 2023
This article has no abstract
Epistemonikos ID: 2305b39c01133aa533325e0235f50a91db126b56
First added on: Feb 17, 2025